[go: up one dir, main page]

WO2020191426A1 - Horse supplement - Google Patents

Horse supplement Download PDF

Info

Publication number
WO2020191426A1
WO2020191426A1 PCT/AU2019/050258 AU2019050258W WO2020191426A1 WO 2020191426 A1 WO2020191426 A1 WO 2020191426A1 AU 2019050258 W AU2019050258 W AU 2019050258W WO 2020191426 A1 WO2020191426 A1 WO 2020191426A1
Authority
WO
WIPO (PCT)
Prior art keywords
horse
supplement
vitamin
feed
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2019/050258
Other languages
French (fr)
Inventor
James Andrew WADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jake Stockfeed Pty Ltd
Original Assignee
Jake Stockfeed Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jake Stockfeed Pty Ltd filed Critical Jake Stockfeed Pty Ltd
Priority to PCT/AU2019/050258 priority Critical patent/WO2020191426A1/en
Publication of WO2020191426A1 publication Critical patent/WO2020191426A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/28—Silicates, e.g. perlites, zeolites or bentonites
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a supplement and a horse feed that is fed to horses suffering from bone weaknesses and defects such as osteochondritis dissecans (OCD).
  • OCD osteochondritis dissecans
  • the present invention also relates to a supplement for strengthening bones and cartilage in the joints of horses.
  • Osteochondritis dissecans is a type of skeletal maturation problem that affects the stifle or hock joint cartilage of horses and often involves the subchondral bone just beneath the cartilage surface.
  • Cartilage in joints with OCD does not form normally which causes the cartilage and subchondral bone to become irregular in thickness and weaker than in normal joints. This can cause cartilage and bone flaps to develop that remain partially attached to the bone or break off and float around in the joint.
  • OCD OCD-related diseases
  • Signs of OCD include lameness and joint swelling.
  • Current treatment involves surgical removal of the abnormal bone and cartilage.
  • the present invention provides a supplement for horses comprising:
  • At least one mineral selected from the group consisting of calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium;
  • the supplement further comprises soybean meal, limestone, and a zeolite.
  • the supplement comprises:
  • vitamin A vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C.
  • the relative amount of 1,25- hydroxycholecalciferol and / or 25-hydroxyvitamin D3 is between about 0.1 to 2 %, preferably about 0.2 to 1 %, and more preferably about 0.5 %.
  • the supplement for horses comprises:
  • the relative percentage amounts of each ingredient are: about 40% Zeolite;
  • the present invention provides a horse feed comprising:
  • At least one nutrition agent at least one nutrition agent.
  • the nutrition agent may be one or more horse nutrients as are known in the art and including grains, roughage, forage and oils.
  • the at least one nutrition agent is selected from oats and / or com and / or barley, preferably oats and / or barley.
  • the present invention provides a method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of a supplement as described above to the horse.
  • the horse is administered between 100 grams and 500 grams of the supplement per day, preferably between about 200 grams and 300 grams of the supplement per day.
  • the present invention provides a method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of a horse feed as described above to the horse.
  • the horse is administered between 1 kg and 5kg of the horse feed per day, preferably between about 2 kg and 3 kg of the horse feed per day.
  • the method further comprises co-administering an anti-inflammatory drug with the supplement and / or horse feed, preferably Pentosan with the supplement and / or horse feed.
  • the bone weakness or bone defect is osteochondritis dissecans (OCD).
  • OCD osteochondritis dissecans
  • administration of the supplement and / or horse feed improves bone density of the horse.
  • administration of the supplement and / or horse feed promotes cyst healing in the horse.
  • administration of the supplement and / or horse feed promotes lesion healing in the horse.
  • administration of the supplement and / or horse feed reduces lucency of the bones in the horse.
  • administration of the supplement and / or horse feed reduces the size of a callus in the horse.
  • the present invention provides a use of 1,25- hydroxycholecalciferol and / or 25-hydroxy vitamin D3 for treating and / or preventing a bone weakness or a bone defect in a horse.
  • the bone weakness or bone defect is osteochondritis dissecans (OCD).
  • OCD osteochondritis dissecans
  • the 1,25- hydroxycholecalciferol and / or 25- hydroxy vitamin D3 is administered to the horse in a supplement and / or horse feed.
  • a method of improving the health of and / or administering nutrition to a horse comprising administering a therapeutically effective amount of a supplement, as described above, or a horse feed comprising said supplement, to the horse.
  • Improving the health of the horse may include one or more of promoting weight gain, promoting healing, improving visual appearance of the coat, improving gait and improving bone health and properties.
  • Bone health and properties may include increasing bone density.
  • Figure 1 A is an X-Ray image of a right stifle subchondral bone cyst of a first horse prior to being fed the supplement of the invention.
  • Figure IB is an X-Ray image of the right stifle subchondral bone cyst of the first horse two months after being fed the supplement of the invention.
  • Figure 1C is an X-Ray image of the right stifle oblique of the first horse prior to being fed the supplement of the invention.
  • Figure ID is an X-Ray image of the right stifle oblique of the first horse two months after being fed the supplement of the invention
  • Figure IE is an X-Ray image of the left stifle oblique of the first horse prior to being fed the supplement of the invention.
  • Figure IF is an X-Ray image of the left stifle oblique of the first horse two months after being fed the supplement of the invention.
  • Figure 1G is an X-Ray image of the right stifle lateral of the first horse prior to being fed the supplement of the invention.
  • Figure 1H is an X-Ray image of the right stifle lateral of the first horse two months after being fed the supplement of the invention.
  • Figure II is an X-Ray image of the left carpus DP of the first horse prior to being fed the supplement of the invention.
  • Figure 1J is an X-Ray image of the left carpus DP of the first horse two months after being fed the supplement of the invention.
  • Figure IK is an X-Ray image of the left carpus DLPMO of the first horse prior to being fed the supplement of the invention.
  • Figure 1L is an X-Ray image of the left carpus DLPMO of the first horse two months after being fed the supplement of the invention.
  • Figure 2A is an X-Ray image of the left carpus DLPMO of the second horse prior to being fed the supplement of the invention.
  • Figure 2B is an X-Ray image of the left carpus DLPMO (large callus) of the second horse two months after being fed the supplement of the invention.
  • Figure 2C is an X-Ray image of the right carpus DP of the second horse prior to being fed the supplement of the invention.
  • Figure 2D is an X-Ray image of the right carpus DP (large callus) of the second horse two months after being fed the supplement of the invention.
  • Figure 2E is an X-Ray image of the right carpus DLPMO of the second horse prior to being fed the supplement of the invention.
  • Figure 2F is an X-Ray image of the right carpus DLPMO (large callus) of the second horse two months after being fed the supplement of the invention.
  • Figure 2G is an X-Ray image of the left carpus DP (large callus) of the second horse prior to being fed the supplement of the invention.
  • Figure 2H is an X-Ray image of the left carpus DP (large callus) of the second horse two months after being fed the supplement of the invention.
  • Figure 3A is an X-Ray image of the left fore fetlock lateral of a third horse prior to being fed the supplement of the invention.
  • Figure 3B is an X-Ray image of the left fore fetlock lateral of the third horse two months after being fed the supplement of the invention.
  • Figure 3C is an X-Ray image of the left carpus DLMPO of the third horse prior to being fed the supplement of the invention.
  • Figure 3D is an X-Ray image of the left carpus DLMPO of the third horse two months after being fed the supplement of the invention.
  • Figure 4A is an X-Ray image of the left carpus DLPMO of a fourth horse prior to being fed the supplement of the invention.
  • Figure 4B is an X-Ray image of the left carpus DLPMO of the fourth horse two months after being fed the supplement of the invention.
  • Figure 4C is an X-Ray image of the left carpus DMPLO of the fourth horse prior to being fed the supplement of the invention.
  • Figure 4D is an X-Ray image of the left carpus DMPLO of the fourth horse two months after being fed the supplement of the invention.
  • the supplement of the present invention is prepared from a selection of the following ingredients:
  • Soyabean meal Calcium carbonate (limestone), Dicalcium Phosphate, Sodium Chloride (NaCl), Sodium Zeolite, Magnesium Oxide, Saccharomyces Cerevisiae (BIOPRO Probiotic), Hy-D premix (contains 1,25- Hydroxycholecalciferol and / or 25-hydroxy vitamin D3; the latter is also known as calcifediol and 25-hydroxycholecalciferol), L-Lysine, MHA-Methionine, Natural feed flavours, Canola oil, Cobalt sulphate, potassium iodide, copper sulphate pentahydrate, ferrous sulphate, manganous oxide, Zinc sulphate & zinc amino acid complex (Availa Zinc), sodium selenite, oxicap (antioxidant), Vitamins A, D3, E, Bl, B2, B6, B12, Biotin, Niacin, Pantothenic acid, Vitamin C, Organic trace
  • the dry matter % stands independent of the other percentages in the table meaning the total dry matter percentage is approximately 97 % dry matter and there will be 3% moisture (not shown in Table 3) which totals 100%.
  • the Ash % reflects the proportion of the diet that represents the ash or mineral level of the diet which in Table 3 is approximately 62% with the balance being vegetable protein meals and non-mineral components. Table 3 does not list all nutrients and hence the percentage values will not add up to 100%.
  • a horse feed according to the present invention is prepared by adding the supplement of the example above to any commercially available horse feed at 10% of the ration. This amount could be weight per volume (w/v), weight per weight (w/w), or volume per volume (v/v) depending on the horse to be treated and the physical properties of the commercial horse feed.
  • Horse feeds typically contain oats and / or barley. Suitable horse feeds (to which the supplement is added) may also be disclosed in literature sources. Preferred horse feeds are those suitable for working or race horses.
  • a young horse is fed 2 kg of the horse feed of the invention per day which delivers 200 grams per head per day of the supplement to the horse.
  • a larger horse in work e.g. a race horse
  • a horse feed containing the example supplement above was fed to four racehorses for two months.
  • X-Ray images of various bones and joints in the horses were recorded at the start and finish of the two-month feeding period. The X-Ray images are shown in figures 1 to 4 and discussed below.
  • This horse had injuries to both front fetlocks, modeling of ICB in the carpus as well as lucency in the left stifle and a bone cyst in the right stifle.
  • the X-ray images show healing of the lucency in the left stifle and the appearance of increased density and a size reduction in the cyst in the right stifle.
  • Another unexpected finding is that the supplement healed the lesions on the horse while the horse was still undergoing training.
  • Figures 1A to ID illustrate how a large subchondral bone cyst distal medial femoral condyle with associated sclerosis in the horse’s right stifle is reduced in size after two months.
  • Figures IE to 1H show the healing of a Distal medial condyle grade 2 lucency lesion in the left and right stifles of the horse after two months.
  • Figures II to 1L show a minor improvement in dorso-lateral proximal ICB modelling in the horse’s left carpus after two months.
  • This horse had bone modelling on the radiocarpal bones on the left knee.
  • the X-ray images show that the modelling has resolved.
  • Figures 3A and 3B show that a lateral sesamoiditis (Fill) in the left fore fetlock has resolved after two months.
  • Figures 3C and 3D show that dorso-lateral distal RCB modelling in the left carpus has resolved after two months.
  • Fourth horse (figures 4 A -4D)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Fodder In General (AREA)

Abstract

A supplement for horses is disclosed. The supplement comprises 1,25-dihydroxycholecalciferol and / or 25-hydroxyvitamin D3; at least one mineral selected from the group consisting of calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium; at least one amino acid selected from the group consisting of lysine, methionine, threonine, tryptophan, and valine; and at least one vitamin selected from the group consisting of vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C. A method of treating a bone weakness or a bone defect, such as osteochondritis dissecans (OCD), is also disclosed.

Description

HORSE SUPPLEMENT
Field
The present invention relates to a supplement and a horse feed that is fed to horses suffering from bone weaknesses and defects such as osteochondritis dissecans (OCD). The present invention also relates to a supplement for strengthening bones and cartilage in the joints of horses.
Background
Osteochondritis dissecans (OCD) is a type of skeletal maturation problem that affects the stifle or hock joint cartilage of horses and often involves the subchondral bone just beneath the cartilage surface. Cartilage in joints with OCD does not form normally which causes the cartilage and subchondral bone to become irregular in thickness and weaker than in normal joints. This can cause cartilage and bone flaps to develop that remain partially attached to the bone or break off and float around in the joint.
Some causes of OCD in horses include trauma, exercise, and poor nutrition through an imbalance in trace minerals in a horse’s diet. Signs of OCD include lameness and joint swelling. Current treatment involves surgical removal of the abnormal bone and cartilage.
It would be desirable to provide an alternative to surgery for treating horses suffering from bone weaknesses and defects such as OCD.
Summary of Invention
In one aspect, the present invention provides a supplement for horses comprising:
1,25- hydroxycholecalciferol and / or 25 -hydroxy vitamin D3;
at least one mineral selected from the group consisting of calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium;
at least one amino acid selected from the group consisting of lysine, methionine, threonine, tryptophan, and valine; and at least one vitamin selected from the group consisting of vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C.
In some embodiments, the supplement further comprises soybean meal, limestone, and a zeolite.
According to some embodiments, the supplement comprises:
calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium;
lysine, methionine, threonine, tryptophan, and valine; and
vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C.
In an embodiment of the supplement, the relative amount of 1,25- hydroxycholecalciferol and / or 25-hydroxyvitamin D3 is between about 0.1 to 2 %, preferably about 0.2 to 1 %, and more preferably about 0.5 %.
In a preferred embodiment, the supplement for horses comprises:
Zeolite;
Limestone;
Soybean Meal Solvent;
Dicalcium Phosphate;
Plain salt (NaCl);
Magnesium Oxide;
Probiotic;
vitamins and minerals;
L-Lysine;
organic zinc, manganese, copper, cobalt and chromium;
Vegetable oil;
methionine;
25-hydroxyvitamin D3; and
Feed flavouring.
In a particularly preferred embodiment of the supplement immediately above, the relative percentage amounts of each ingredient are: about 40% Zeolite;
about 20% Limestone;
about 10.89% Soybean Meal Solvent;
about 8% dicalcium Phosphate;
about 5% plain salt (NaCl);
about 5% magnesium Oxide;
about 5% probiotic;
about 2% vitamins and minerals;
about 1% L- Lysine;
about 1% organic zinc, manganese, copper, cobalt and chromium;
about 1% vegetable oil;
about 0.6% methionine;
about 0.5% 25-hydroxy vitamin D3; and
about 0.01% feed flavouring.
In another aspect, the present invention provides a horse feed comprising:
the supplement as described above; and
at least one nutrition agent.
The nutrition agent may be one or more horse nutrients as are known in the art and including grains, roughage, forage and oils.
In a preferred embodiment, the at least one nutrition agent is selected from oats and / or com and / or barley, preferably oats and / or barley.
In another aspect, the present invention provides a method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of a supplement as described above to the horse.
In some embodiments of the method, the horse is administered between 100 grams and 500 grams of the supplement per day, preferably between about 200 grams and 300 grams of the supplement per day. In another aspect, the present invention provides a method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of a horse feed as described above to the horse.
According to some embodiments of the method, the horse is administered between 1 kg and 5kg of the horse feed per day, preferably between about 2 kg and 3 kg of the horse feed per day.
In some embodiments, the method further comprises co-administering an anti-inflammatory drug with the supplement and / or horse feed, preferably Pentosan with the supplement and / or horse feed.
In one embodiment, the bone weakness or bone defect is osteochondritis dissecans (OCD). According to another embodiment, administration of the supplement and / or horse feed improves bone density of the horse.
In one embodiment, administration of the supplement and / or horse feed promotes cyst healing in the horse.
In another embodiment, administration of the supplement and / or horse feed promotes lesion healing in the horse.
According to another embodiment, administration of the supplement and / or horse feed reduces lucency of the bones in the horse.
In one embodiment, administration of the supplement and / or horse feed reduces the size of a callus in the horse. In another aspect, the present invention provides a use of 1,25- hydroxycholecalciferol and / or 25-hydroxy vitamin D3 for treating and / or preventing a bone weakness or a bone defect in a horse.
In some embodiments of the use, the bone weakness or bone defect is osteochondritis dissecans (OCD). According to some embodiments of the use, the 1,25- hydroxycholecalciferol and / or 25- hydroxy vitamin D3 is administered to the horse in a supplement and / or horse feed.
In one aspect, there is provided a method of improving the health of and / or administering nutrition to a horse comprising administering a therapeutically effective amount of a supplement, as described above, or a horse feed comprising said supplement, to the horse.
Improving the health of the horse may include one or more of promoting weight gain, promoting healing, improving visual appearance of the coat, improving gait and improving bone health and properties.
Bone health and properties may include increasing bone density. Brief Description of Drawings
Figure 1 A is an X-Ray image of a right stifle subchondral bone cyst of a first horse prior to being fed the supplement of the invention.
Figure IB is an X-Ray image of the right stifle subchondral bone cyst of the first horse two months after being fed the supplement of the invention. Figure 1C is an X-Ray image of the right stifle oblique of the first horse prior to being fed the supplement of the invention.
Figure ID is an X-Ray image of the right stifle oblique of the first horse two months after being fed the supplement of the invention
Figure IE is an X-Ray image of the left stifle oblique of the first horse prior to being fed the supplement of the invention.
Figure IF is an X-Ray image of the left stifle oblique of the first horse two months after being fed the supplement of the invention.
Figure 1G is an X-Ray image of the right stifle lateral of the first horse prior to being fed the supplement of the invention. Figure 1H is an X-Ray image of the right stifle lateral of the first horse two months after being fed the supplement of the invention.
Figure II is an X-Ray image of the left carpus DP of the first horse prior to being fed the supplement of the invention.
Figure 1J is an X-Ray image of the left carpus DP of the first horse two months after being fed the supplement of the invention.
Figure IK is an X-Ray image of the left carpus DLPMO of the first horse prior to being fed the supplement of the invention.
Figure 1L is an X-Ray image of the left carpus DLPMO of the first horse two months after being fed the supplement of the invention.
Figure 2A is an X-Ray image of the left carpus DLPMO of the second horse prior to being fed the supplement of the invention.
Figure 2B is an X-Ray image of the left carpus DLPMO (large callus) of the second horse two months after being fed the supplement of the invention.
Figure 2C is an X-Ray image of the right carpus DP of the second horse prior to being fed the supplement of the invention.
Figure 2D is an X-Ray image of the right carpus DP (large callus) of the second horse two months after being fed the supplement of the invention.
Figure 2E is an X-Ray image of the right carpus DLPMO of the second horse prior to being fed the supplement of the invention.
Figure 2F is an X-Ray image of the right carpus DLPMO (large callus) of the second horse two months after being fed the supplement of the invention.
Figure 2G is an X-Ray image of the left carpus DP (large callus) of the second horse prior to being fed the supplement of the invention. Figure 2H is an X-Ray image of the left carpus DP (large callus) of the second horse two months after being fed the supplement of the invention.
Figure 3A is an X-Ray image of the left fore fetlock lateral of a third horse prior to being fed the supplement of the invention.
Figure 3B is an X-Ray image of the left fore fetlock lateral of the third horse two months after being fed the supplement of the invention.
Figure 3C is an X-Ray image of the left carpus DLMPO of the third horse prior to being fed the supplement of the invention.
Figure 3D is an X-Ray image of the left carpus DLMPO of the third horse two months after being fed the supplement of the invention.
Figure 4A is an X-Ray image of the left carpus DLPMO of a fourth horse prior to being fed the supplement of the invention.
Figure 4B is an X-Ray image of the left carpus DLPMO of the fourth horse two months after being fed the supplement of the invention.
Figure 4C is an X-Ray image of the left carpus DMPLO of the fourth horse prior to being fed the supplement of the invention.
Figure 4D is an X-Ray image of the left carpus DMPLO of the fourth horse two months after being fed the supplement of the invention.
Description of Embodiments
Supplement
The supplement of the present invention is prepared from a selection of the following ingredients:
Soyabean meal, Calcium carbonate (limestone), Dicalcium Phosphate, Sodium Chloride (NaCl), Sodium Zeolite, Magnesium Oxide, Saccharomyces Cerevisiae (BIOPRO Probiotic), Hy-D premix (contains 1,25- Hydroxycholecalciferol and / or 25-hydroxy vitamin D3; the latter is also known as calcifediol and 25-hydroxycholecalciferol), L-Lysine, MHA-Methionine, Natural feed flavours, Canola oil, Cobalt sulphate, potassium iodide, copper sulphate pentahydrate, ferrous sulphate, manganous oxide, Zinc sulphate & zinc amino acid complex (Availa Zinc), sodium selenite, oxicap (antioxidant), Vitamins A, D3, E, Bl, B2, B6, B12, Biotin, Niacin, Pantothenic acid, Vitamin C, Organic trace minerals, Zinc, Cobalt, Manganese, Copper & Chromium yeast (Availa 4 + Cr), vegetable oil. Availa 4 contains organic zinc, manganese, copper and cobalt.
The relative amounts of each ingredient in a non-limiting example supplement are shown in the following Table 1:
Figure imgf000009_0001
Table 1
The ingredients in Table 1 are readily available from commercial and / or literature sources. The composition of the Horse Premix is detailed in the following Table 2:
Figure imgf000009_0002
Figure imgf000009_0003
Figure imgf000010_0001
Table 2
Upon mixing, the nutrient composition of the example supplement in Table 1 above is shown in the following Table 3:
Figure imgf000011_0001
With reference to Table 3, the dry matter % stands independent of the other percentages in the table meaning the total dry matter percentage is approximately 97 % dry matter and there will be 3% moisture (not shown in Table 3) which totals 100%. The Ash % reflects the proportion of the diet that represents the ash or mineral level of the diet which in Table 3 is approximately 62% with the balance being vegetable protein meals and non-mineral components. Table 3 does not list all nutrients and hence the percentage values will not add up to 100%.
Horse Feed
A horse feed according to the present invention is prepared by adding the supplement of the example above to any commercially available horse feed at 10% of the ration. This amount could be weight per volume (w/v), weight per weight (w/w), or volume per volume (v/v) depending on the horse to be treated and the physical properties of the commercial horse feed. Horse feeds typically contain oats and / or barley. Suitable horse feeds (to which the supplement is added) may also be disclosed in literature sources. Preferred horse feeds are those suitable for working or race horses.
Dosage of the horse feed
A young horse is fed 2 kg of the horse feed of the invention per day which delivers 200 grams per head per day of the supplement to the horse. A larger horse in work (e.g. a race horse) is fed 3 kg of the horse feed per day which delivers 300 grams per head per day of the supplement to the horse.
Effect of the supplement on horses
A horse feed containing the example supplement above was fed to four racehorses for two months. X-Ray images of various bones and joints in the horses were recorded at the start and finish of the two-month feeding period. The X-Ray images are shown in figures 1 to 4 and discussed below.
First horse (figures 1A -1L)
This horse had injuries to both front fetlocks, modeling of ICB in the carpus as well as lucency in the left stifle and a bone cyst in the right stifle. The X-ray images show healing of the lucency in the left stifle and the appearance of increased density and a size reduction in the cyst in the right stifle. There were also improvements in the ICB. Another unexpected finding is that the supplement healed the lesions on the horse while the horse was still undergoing training.
Figures 1A to ID illustrate how a large subchondral bone cyst distal medial femoral condyle with associated sclerosis in the horse’s right stifle is reduced in size after two months. Figures IE to 1H show the healing of a Distal medial condyle grade 2 lucency lesion in the left and right stifles of the horse after two months. Figures II to 1L show a minor improvement in dorso-lateral proximal ICB modelling in the horse’s left carpus after two months.
Second horse (figures 2A -2H)
This horse had a large callus on the MCIII (cannon/shin bones). The X-Ray images showed that the callus on both MCIII resolved. Figures 2A to 2H show that a dorsal proximal medial condyle III callus on the left carpus and the right carpus has resolved after two months.
Third horse (figures 3A -3D)
This horse had bone modelling on the radiocarpal bones on the left knee. The X-ray images show that the modelling has resolved. Figures 3A and 3B show that a lateral sesamoiditis (Fill) in the left fore fetlock has resolved after two months. Figures 3C and 3D show that dorso-lateral distal RCB modelling in the left carpus has resolved after two months. Fourth horse (figures 4 A -4D)
This horse had bone modelling of the radial carpal bone (RCB). In short, the X-Ray images show the modelling on the RCB had resolved. Figures 4A to 4D show that dorso-lateral distal RCB modelling in the horse’s left carpus has resolved after two months. In summary, the results show horses treated with the supplement showed significant
improvement and healing of the bone modelling. The results further showed the supplement contributed to the healing and increase in bone density of the cyst in the stifles.

Claims

1. A supplement for horses comprising:
1,25- hydroxycholecalciferol and / or 25-hydroxy vitamin D3;
at least one mineral selected from the group consisting of calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium;
at least one amino acid selected from the group consisting of lysine, methionine, threonine, tryptophan, and valine; and
at least one vitamin selected from the group consisting of vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C.
2. The supplement of claim 1, further comprising soybean meal, limestone, and a zeolite.
3. The supplement of claims 1 or 2, wherein the supplement comprises:
calcium, phosphorus, magnesium, potassium, chloride, cobalt, iodine, copper, manganese, zinc, selenium, and chromium;
lysine, methionine, threonine, tryptophan, and valine; and
vitamin A, vitamin D3, vitamin E, vitamin K, thiamine Bl, riboflavin B2, niacin B3, vitamin B6, vitamin B12, biotin H-2, folic acid B9, and vitamin C.
4. The supplement of any one of claim 1 to 3, wherein the relative amount of 1,25- hydroxycholecalciferol and / or 25 -hydroxy vitamin D3 is between about 0.1 to 2 %, preferably about 0.2 to 1 %, and more preferably about 0.5 %.
5. A supplement for horses comprising:
Zeolite;
Limestone;
Soybean Meal Solvent;
Dicalcium Phosphate;
Plain salt (NaCl);
Magnesium Oxide;
Probiotic;
vitamins and minerals; L-Lysine;
organic zinc, manganese, copper, cobalt and chromium;
Vegetable oil;
methionine;
25-hydroxy vitamin D3; and
Feed flavouring.
6. The supplement of claim 5, wherein the relative percentage amounts of each ingredient are: about 40% Zeolite;
about 20% Limestone;
about 10.89% Soybean Meal Solvent;
about 8% dicalcium Phosphate;
about 5% plain salt (NaCl);
about 5% magnesium Oxide;
about 5% probiotic;
about 2% vitamins and minerals;
about 1% L-Lysine;
about 1% organic zinc, manganese, copper, cobalt and chromium;
about 1% vegetable oil;
about 0.6% methionine;
about 0.5% 25-hydroxy vitamin D3; and
about 0.01% feed flavouring.
7. A horse feed comprising:
the supplement of any one of the preceding claims; and
oats and / or barley.
8. A method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of a supplement of any one claims 1 to 6 to the horse.
9. The method of any one of claim 8 wherein the horse is administered between 100 grams and 500 grams of the supplement per day, preferably between about 200 grams and 300 grams of the supplement per day.
10. A method of treating and / or preventing a bone weakness or a bone defect in a horse comprising administering a therapeutically effective amount of the horse feed of claim 7 to the horse.
11. The method of any one of claim 10 wherein the horse is administered between 1 kg and 5kg of the horse feed per day, preferably between about 2 kg and 3 kg of the horse feed per day.
12. The method of any one of claims 8 to 11 further comprising co-administering an anti inflammatory drug with the supplement and / or horse feed, preferably Pentosan with the supplement and / or horse feed.
13. The method of any one of claims 8 to 12, wherein the bone weakness or bone defect is osteochondritis dissecans (OCD).
14. The method of any one of claims 8 to 13 wherein administration of the supplement and / or horse feed improves bone density of the horse.
15. The method of any one of claims 8 to 14 wherein administration of the supplement and / or horse feed promotes cyst healing in the horse.
16. The method of any one of claims 8 to 15 wherein administration of the supplement and / or horse feed promotes lesion healing in the horse.
17. The method of any one of claims 8 to 16 wherein administration of the supplement and / or horse feed reduces lucency of the bones in the horse.
18. The method of any one of claims 8 to 17 wherein administration of the supplement and / or horse feed reduces the size of a callus in the horse.
19. Use of 1,25- hydroxycholecalciferol and / or 25 -hydroxy vitamin D3 for treating and / or preventing a bone weakness or a bone defect in a horse.
20. The use of claim 19, wherein the bone weakness or bone defect is osteochondritis dissecans (OCD).
21. The use of claim 19 or 20, wherein the 1,25- hydroxycholecalciferol and / or 25- hydroxyvitamin D3 is administered to the horse in a supplement and / or horse feed.
PCT/AU2019/050258 2019-03-22 2019-03-22 Horse supplement Ceased WO2020191426A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2019/050258 WO2020191426A1 (en) 2019-03-22 2019-03-22 Horse supplement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2019/050258 WO2020191426A1 (en) 2019-03-22 2019-03-22 Horse supplement

Publications (1)

Publication Number Publication Date
WO2020191426A1 true WO2020191426A1 (en) 2020-10-01

Family

ID=72608359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2019/050258 Ceased WO2020191426A1 (en) 2019-03-22 2019-03-22 Horse supplement

Country Status (1)

Country Link
WO (1) WO2020191426A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55139320A (en) * 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
US4929610A (en) * 1985-07-01 1990-05-29 Hoffmann-La Roche Inc. Composition which contain hydroxylated derivatives of vitamin D3
US20050064018A1 (en) * 2003-09-22 2005-03-24 Carlos Simoes-Nunes Use of vitamin D compounds
WO2005027650A1 (en) * 2003-09-22 2005-03-31 Dsm Ip Assets B.V. Vitamin containing pet food compositions
WO2013174148A1 (en) * 2012-05-25 2013-11-28 Dsm Ip Assets B.V. Method for improving growth performance and/or bone performance of animal
CN106913856A (en) * 2017-04-07 2017-07-04 南通市第人民医院 A kind of animal specific calcium tablet and preparation method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55139320A (en) * 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
US4929610A (en) * 1985-07-01 1990-05-29 Hoffmann-La Roche Inc. Composition which contain hydroxylated derivatives of vitamin D3
US20050064018A1 (en) * 2003-09-22 2005-03-24 Carlos Simoes-Nunes Use of vitamin D compounds
WO2005027650A1 (en) * 2003-09-22 2005-03-31 Dsm Ip Assets B.V. Vitamin containing pet food compositions
WO2013174148A1 (en) * 2012-05-25 2013-11-28 Dsm Ip Assets B.V. Method for improving growth performance and/or bone performance of animal
CN106913856A (en) * 2017-04-07 2017-07-04 南通市第人民医院 A kind of animal specific calcium tablet and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RABAR, JOINT & HOOF SUPPLEMENT, 30 April 2019 (2019-04-30), XP55742968, Retrieved from the Internet <URL:https://web.archive.org/web/20180909032753/http://www.rabar.com.au/images/downloads/joint_hoof_supplement.pdf> [retrieved on 20190909] *

Similar Documents

Publication Publication Date Title
DE69429920T2 (en) REPLACEMENT FEEDING ADDITIVES FOR LIVING LIVESTOCK
EP2983495B1 (en) Feeding methods and systems for young livestock animals using sensory compounds
EP0998203A1 (en) Process for optimizing milk production
US6911215B2 (en) Treating arthritis in animals with dietary supplements
MXPA04009079A (en) Use of vitamin d compounds.
CA2742123C (en) Methods for altering food intake, modifying nutrient digestibility and altering stool quality and/or stool frequency
US7351437B2 (en) Pet food compositions comprising electrostatically charged gelatin
US20060246173A1 (en) Feed compositions and methods of making and using the same
JP2007505637A (en) Vitamin-containing pet food composition
AU2003202125B2 (en) An equine feed product
WO1998043634A1 (en) A method for improving the weight gain and feed conversion efficiency of swine
CA1308294C (en) Method of feeding ketoisocaproate to cattle and sheep
WO2020191426A1 (en) Horse supplement
AU2003202125A1 (en) An equine feed product
Rezende et al. Effect of two different nutritional programs on orthopedic alterations in Mangalarga Marchador foals
Skiba et al. The performance and body composition of growing pigs during protein or energy deficiency and subsequent realimentation
CA2314042C (en) Horse feed
Duren Delivering essential nutrients to young, growing horses
Diaz Effects of 1-α-hydroxycholecalciferol and Other Vitamin D Analogs on Live Performance, Bone Development, Meat Yield and Quality, and Mineral Digestibility on Broilers
de Andrade et al. Morphometric characteristics of finishing pigs fed cottonseed meal
Jesse et al. Effect of supplemental potassium in the receiving diet and form of antibiotic on feeder pig performance
NL2007581C2 (en) Method for preventing osteochondrosis.
Lawrence Nutrient requirements and balancing rations for horses
DE202024001948U1 (en) Composition to support bone growth and development
Brief RD Coffey, CV Maxwell? and AC Clutterº

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19921589

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19921589

Country of ref document: EP

Kind code of ref document: A1